Jyong Biotech (MENS) vs OnKure Therapeutics (OKUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OnKure Therapeutics (OKUR) has outperformed Jyong Biotech (MENS) over the past year, gaining 4.7% versus a loss of 95.3%. OnKure Therapeutics is the larger company by market cap ($111.2 million vs $110.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | OKUR |
|---|---|---|
| Share price | $1.45 | $2.70 |
| Market cap | $110.24M | $111.21M |
| 1-day change | -17.14% | -2.17% |
| YTD return | -63.29% | -6.90% |
| 1-year return | -95.28% | +4.65% |
| 5-year return | — | -96.16% |
| EPS (TTM) | $-0.06 | $-2.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-4.67M | $-59.52M |
| 52-week high | $38.88 | $5.38 |
| 52-week low | $1.43 | $2.01 |
| Distance from 52-week high | -96.27% | -49.81% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +464.81% |
| Average volume | 44.23K | 335.78K |
| Shares outstanding | 74.23M | 40.50M |
| Employees | 27 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKUR has outperformed MENS by 99.9 percentage points over the past year.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
MENS vs OKUR FAQ
Which is bigger, Jyong Biotech or OnKure Therapeutics?
OnKure Therapeutics (OKUR) is larger, with a market capitalization of $111.21M compared with $110.24M for Jyong Biotech (MENS).
Which stock has performed better over the past year, MENS or OKUR?
OKUR returned +4.65% over the past 12 months, compared with -95.28% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and OnKure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.